GC Medical Science KRX:142280KOSDAQ
녹십자엠에스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, GC Medical Science reported revenue of ₩27.1bn, down 10.9% year on year, and operating profit of ₩743m. GC Medical Science (녹십자엠에스) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
GC Medical Science quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩27.1bn | -10.9% | ₩743m margin 2.7% | −₩4.0bn |
| Q1 2026 | ₩23.6bn | -11.1% | ₩292m margin 1.2% | ₩221m |
| Q4 2025 derived | ₩25.0bn | -9.7% | ₩390m margin 1.6% | ₩333m |
| Q3 2025 | ₩26.4bn | -1.8% | ₩944m margin 3.6% | ₩1.4bn |
| Q2 2025 | ₩30.4bn | +19.5% | ₩1.1bn margin 3.5% | ₩2.4bn |
| Q1 2025 | ₩26.5bn | +11.7% | ₩495m margin 1.9% | −₩727m |
| Q4 2024 derived | ₩27.8bn | +17.5% | ₩971m margin 3.5% | ₩2.1bn |
| Q3 2024 | ₩26.9bn | +14.6% | ₩931m margin 3.5% | ₩179m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
GC Medical Science top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest GC Medical Science news Korean headlines
No articles yet.